

The Israel Heart Society and Pfizer Pharmaceuticals announce:

CLINICALLY ORIENTED FELLOWSHIP 2007

We are pleased to announce that the Israel Heart Society and Pfizer Pharmaceuticals will again co-sponsor a successful fellow in a one-year Cardiovascular Drug Development fellowship at the Pfizer Research and Global Development campus in Groton, CT (USA).

The 2003 IHS-Pfizer cardiovascular fellow successfully completed 6 months at Pfizer's Global Research and Development facility in Sandwich, England. Her primary project was a study exploring the utility of sildenafil in hypertension. She describes the experience as "excellent and challenging." Due to its great success and participants' recommendations, the fellowship is extended to a full one-year with the option to continue an additional year.

The 2006 IHS-Pfizer cardiovascular fellow successfully completed 12 months at Pfizer's Global Research and Development facility in Groton, USA. During the fellowship at "Pfizer" the fellow joined as an integrated member to a group of scientists from the cardiovascular therapeutic area, working on a large panel of novel biomarkers of atherosclerosis. In addition the fellow was exposed to ongoing programs of new therapies for atherosclerosis, participated in drug development meetings, conferences and courses.

The purpose of the joint IHS-Pfizer fellowship is to provide one cardiologist with the opportunity to be exposed to *clinically oriented research* and experience the discovery and development of pharmaceuticals directed to cardiovascular disease with the emphasis on the field of Atherosclerosis.

The strength of the Israel Heart Society-Pfizer Program is that it enables the fellow to work on Pfizer-related development projects at Pfizer facilities. It gives the fellow a wide range of experiences in the art and science of drug development as well as the difficult scientific problems that are part of everyday work in the pharmaceutical industry.

The fellow will be exposed to the science of drug development of cardiovascular compounds, and be taught state-of-the-art methods in study design and biomarker development in clinical cardiovascular investigation in drug development. He or she will experience a unique multidisciplinary teamwork environment and Pfizer's research strength, locally and worldwide.

The program reflects Pfizer's continuum of existing processes for fostering young experts and encouraging next generation of opinion leaders to establish clinical research programs, facilities and excellence.

The program is intended for Israeli cardiology graduates (shortly after Board examinations or during his/her final year of training), as part of "basic research program" – as per the requirements of the National Board Committee.

IHS and Pfizer will support the fellow with a J-1 visa, a competitive stipend, and relocation/health insurance expenses, as well as scientific meeting travel assistance.

Applicants who are interested in participating in this program are requested to submit the following:

- an application letter indicating research area of interests
- an updated CV
- a letter of commitment to return to Israel after a maximum of two years abroad for at least one year of employment at his/her current department
- a letter of recommendation from Chief of Cardiology/Chief of Service
- a letter of commitment from the Chief of Cardiology/Chief of Service and Director of the hospital to accept the fellow back to the department for at least one year after completion of the fellowship

The candidate must be able to communicate well in written and spoken English. Previous experience in research is not necessary but advantageous. The fellow will be expected to write a summary of his or her experience intended for publication in the IHS Newsletter

Applications should be submitted to the Israel Heart Society office no later than **March 18, 2007**. Applicants should expect to be interviewed in English.

Final decision about the first candidate is expected in April 2007.

Fellowship will start no later than September 2007.

The Israel Heart Society would like to express its gratitude to Pfizer for the generous support of this exciting program.

Israel Heart Society
Pfizer Pharmaceuticals